Literature DB >> 27815444

An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.

Yajing Chen1, Richard Wilson2, Sijy O'Dell3, Javier Guenaga2, Yu Feng2, Karen Tran2, Chi-I Chiang4, Heather E Arendt5, Joanne DeStefano5, John R Mascola3, Richard T Wyatt1,2,6, Yuxing Li7,2,4.   

Abstract

Elicitation of broadly neutralizing Ab (bNAb) responses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary receptor CD4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished. However, a large number of CD4bs-directed bNAbs have been isolated from HIV-1-infected individuals. Comparison of the routes of binding used by the CD4bs-directed bNAbs from patients and the vaccine-elicited CD4bs-directed mAbs indicates that the latter fail to neutralize primary virus isolates because they approach the Env spike with a vertical angle and contact the specific surface residues occluded in the native spike, including the bridging sheet on gp120. To preferentially expose the CD4bs and direct the immune response away from the bridging sheet, resulting in an altered angle of approach, we engineered an immunogen consisting of gp120 core in complex with the prototypic CD4-induced Ab, 17b. This mAb directly contacts the bridging sheet but not the CD4bs. The complex was further stabilized by chemical crosslinking to prevent dissociation. Rabbits immunized with the crosslinked complex displayed earlier affinity maturation, achieving tier 1 virus neutralization compared with animals immunized with gp120 core alone. Immunization with the crosslinked complex induced transient Ab responses with binding specificity similar to the CD4bs-directed bNAbs. mAbs derived from complex-immunized rabbits displayed footprints on gp120 more distal from the bridging sheet as compared with previous vaccine-elicited CD4bs Abs, indicating that Env-Ab complexes effectively dampen immune responses to undesired immunodominant bridging sheet determinants.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815444      PMCID: PMC5117957          DOI: 10.4049/jimmunol.1601134

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.

Authors:  W Zhang; A P Godillot; R Wyatt; J Sodroski; I Chaiken
Journal:  Biochemistry       Date:  2001-02-13       Impact factor: 3.162

2.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

Authors:  Seung-Yong Seong; Polly Matzinger
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

3.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

Review 4.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Authors:  Christopher Sundling; Yuxing Li; Nick Huynh; Christian Poulsen; Richard Wilson; Sijy O'Dell; Yu Feng; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Sci Transl Med       Date:  2012-07-11       Impact factor: 17.956

7.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

8.  Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells.

Authors:  J G Sodroski; C A Rosen; W A Haseltine
Journal:  Science       Date:  1984-07-27       Impact factor: 47.728

9.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  9 in total

1.  Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Authors:  Jacob T Martin; Christopher A Cottrell; Aleksandar Antanasijevic; Diane G Carnathan; Benjamin J Cossette; Chiamaka A Enemuo; Etse H Gebru; Yury Choe; Federico Viviano; Stephanie Fischinger; Talar Tokatlian; Kimberly M Cirelli; George Ueda; Jeffrey Copps; Torben Schiffner; Sergey Menis; Galit Alter; William R Schief; Shane Crotty; Neil P King; David Baker; Guido Silvestri; Andrew B Ward; Darrell J Irvine
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

2.  HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Authors:  Yimeng Wang; Sijy O'Dell; Hannah L Turner; Chi-I Chiang; Lin Lei; Javier Guenaga; Richard Wilson; Paola Martinez-Murillo; Nicole Doria-Rose; Andrew B Ward; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam; Yuxing Li
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

3.  Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Authors:  Johannes S Gach; Kane J V Mara; Celia C LaBranche; Marit J van Gils; Laura E McCoy; P J Klasse; David C Montefiori; Rogier W Sanders; John P Moore; Donald N Forthal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.

Authors:  Catarina E Hioe; Rajnish Kumar; Chitra Upadhyay; Muzafar Jan; Alisa Fox; Vincenza Itri; Kristina K Peachman; Mangala Rao; Lily Liu; Nathan C Lo; Michael Tuen; Xunqing Jiang; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

Review 5.  Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases.

Authors:  Alex F Tang; Gospel Enyindah-Asonye; Catarina E Hioe
Journal:  Vaccines (Basel)       Date:  2021-02-02

Review 6.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

7.  Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.

Authors:  Benjamin J Read; Lori Won; John C Kraft; Isaac Sappington; Aereas Aung; Shengwei Wu; Julia Bals; Chengbo Chen; Kelly K Lee; Daniel Lingwood; Neil P King; Darrell J Irvine
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

8.  HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.

Authors:  Andrey Galkin; Yajing Chen; Javier Guenaga; Sijy O'Dell; Roderico Acevedo; James J Steinhardt; Yimeng Wang; Richard Wilson; Chi-I Chiang; Nicole Doria-Rose; Alexander V Grishaev; John R Mascola; Yuxing Li
Journal:  J Immunol       Date:  2020-02-17       Impact factor: 5.426

9.  Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Authors:  Jacob T Martin; Christopher A Cottrell; Aleksandar Antanasijevic; Diane G Carnathan; Benjamin J Cossette; Chiamaka A Enemuo; Etse H Gebru; Yury Choe; Federico Viviano; Stephanie Fischinger; Talar Tokatlian; Kimberly M Cirelli; George Ueda; Jeffrey Copps; Torben Schiffner; Sergey Menis; Galit Alter; William R Schief; Shane Crotty; Neil P King; David Baker; Guido Silvestri; Andrew B Ward; Darrell J Irvine
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.